Table 2 Sites of microbiologically... | American Society of Hematology

Table 2

Sites of microbiologically documented infections

Site	Phase 1, N = 635		Phase 2				Phase 3, N = 318
	Phase 1, N = 635		Ida-DCTERregimen, N = 342		Fludarabineregimen, N = 313		Phase 3, N = 318
	No.	%	No.	%	Np.	%	No.	%
Blood	357	56	191	56	190	61	219	69
Pulmonary	67	11	48	14	54	17	35	11
Gastrointestinal tract	90	14	30	9	23	7	11	3
Skin	33	5	20	6	11	4	15	5
Central nervous system	2	<1	0	0	1	0.3	1	0.3
Urinary tract	32	5	20	6	13	4	9	3
Central venous catheter	6	2	3	1	0	0	5	2
Liver	10	2	8	2	3	1	7	2
Sinus, upper respiratory tract	17	3	14	4	6	2	10	3
Other	21	3	8	2	12	4	6	2

Site	Phase 1, N = 635		Phase 2				Phase 3, N = 318
	Phase 1, N = 635		Ida-DCTERregimen, N = 342		Fludarabineregimen, N = 313		Phase 3, N = 318
	No.	%	No.	%	Np.	%	No.	%
Blood	357	56	191	56	190	61	219	69
Pulmonary	67	11	48	14	54	17	35	11
Gastrointestinal tract	90	14	30	9	23	7	11	3
Skin	33	5	20	6	11	4	15	5
Central nervous system	2	<1	0	0	1	0.3	1	0.3
Urinary tract	32	5	20	6	13	4	9	3
Central venous catheter	6	2	3	1	0	0	5	2
Liver	10	2	8	2	3	1	7	2
Sinus, upper respiratory tract	17	3	14	4	6	2	10	3
Other	21	3	8	2	12	4	6	2

IdaDCTER regimen indicates idarubicin, daunomycin, cytarabine, thioguanine, etoposide, and dexamethasone; and fludarabine-based regimen, fludarabine, cytosine arabinoside, and idarubicin.